PCM
WHWK

Prelude Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Prelude Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,283
Closed -$35.5K – 1597
2026
Q1 		$35.5K Sell
10,283
-8,513
-45% -$26.7K ﹤0.01% 1144
2025
Q4 		$45.5K Buy
+18,796
New +$43.1K ﹤0.01% 1242
2025
Q2 		– Sell
-10,197
Closed -$18.2K – 1454
2025
Q1 		$18.2K Sell
10,197
-2,700
-21% -$7.05K ﹤0.01% 1132
2024
Q4 		$40.7K Sell
12,897
-4,900
-28% -$11.1K ﹤0.01% 1155
2024
Q3 		$36.7K Sell
17,797
-18,400
-51% -$29.7K ﹤0.01% 1225
2024
Q2 		$52.8K Sell
36,197
-400
-1% -$741 ﹤0.01% 1144
2024
Q1 		$85.6K Buy
36,597
+10,200
+39% +$19.7K ﹤0.01% 1216
2023
Q4 		$53.3K Buy
26,397
+4,500
+21% +$18.9K ﹤0.01% 1072
2023
Q3 		$106K Buy
21,897
+10,823
+98% +$62.9K 0.01% 987
2023
Q2 		$75.7K Buy
+11,074
New +$86.1K ﹤0.01% 953

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prelude Capital Management's WHWK Position: Q2 2026 in Review

Prelude Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2026, closing a stake of 10,283 shares — an estimated $35.5K sold.

Prelude Capital Management first reported a position in WHWK in Q2 2023 and held it in 10 quarters. The position peaked at $106K in Q3 2023. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Prelude Capital Management reported no remaining Whitehawk Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 10,283 Whitehawk Therapeutics shares in Q2 2026, an estimated $35.5K.
  • Prelude Capital Management first reported a position in Whitehawk Therapeutics in Q2 2023 and held it in 10 quarters.
  • Prelude Capital Management's Whitehawk Therapeutics position peaked at $106K in Q3 2023.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.